Lab Results: Thrivikraman Subramanian Irene Rummel, PA-C

Download as pdf or txt
Download as pdf or txt
You are on page 1of 3

Patient: Thrivikraman Subramanian

MRN: 5188645
Irene Rummel, PA-C

Lab results
Patient Provider
Thrivikraman Subramanian Irene Rummel, PA-C
Male Urgent Care, Coronavirus Testing - Urgent Care

+1 415-613-0791 +1 510-686-3621
Carbon Health
2920 Telegraph Ave
Berkeley, CA 94705
Phone: +1510-686-3621
Fax: +1 888-972-1912
[email protected]

LABS DONE AT AN OUTSIDE FACILITY

Received Jul 5, 2022 at 10:03pm

Hepatitis B Core Antibody, Total, with Reflex to IgM (Final Results)

HEPATITIS B CORE AB TOTAL NON-REACTIVE


Normal: NON-REACTIVE Normal
Final

Hepatitis B Surface Antigen with Reflex Confirmation (Final Results)

HEPATITIS B SURFACE ANTIGEN NON-REACTIVE


Normal: NON-REACTIVE Normal
Final

Hepatitis C Antibody with Reflex to HCV, RNA, Quantitative, Real-Time PCR (Final Results)

HEPATITIS C ANTIBODY NON-REACTIVE


Normal: NON-REACTIVE Normal
Final

INDEX 0.01
Normal: <1.00 Normal
Final

HCV antibody was non-reactive. There is no laboratory


evidence of HCV infection.
In most cases, no further action is required. However,
if recent HCV exposure is suspected, a test for HCV RNA
(test code 35645) is suggested.
For additional information please refer to
http://education.questdiagnostics.com/faq/FAQ22v1
(This link is being provided for informational/
educational purposes only.)

Page 1
/
3
Patient: Thrivikraman Subramanian
MRN: 5188645
Irene Rummel, PA-C

HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes (Final Results)

HIV AG/AB, 4TH GEN NON-REACTIVE


Normal: NON-REACTIVE Normal
Final

HIV-1 antigen and HIV-1/HIV-2 antibodies were not


detected. There is no laboratory evidence of HIV
infection.
PLEASE NOTE: This information has been disclosed to
you from records whose confidentiality may be
protected by state law. If your state requires such
protection, then the state law prohibits you from
making any further disclosure of the information
without the specific written consent of the person
to whom it pertains, or as otherwise permitted by law.
A general authorization for the release of medical or
other information is NOT sufficient for this purpose.
For additional information please refer to
http://education.questdiagnostics.com/faq/FAQ106
(This link is being provided for informational/
educational purposes only.)
The performance of this assay has not been clinically
validated in patients less than 2 years old.

STI MALE URETHRITIS PANEL (Final Results)

CHLAMYDIA TRACHOMATIS RNA, TMA, UROGENITAL NOT DETECTED


Normal
Final

NEISSERIA GONORRHOEAE RNA, TMA, UROGENITAL NOT DETECTED


Normal
Final

TRICHOMONAS VAGINALIS RNA QUALITATIVE TMA, MALES NOT DETECTED


Normal
Final

MYCOPLASMA GENITALIUM, rRNA, TMA NOT DETECTED


Normal
Final

ASSAY DETAILS SEE NOTE


Final

REFERENCE RANGE: NOT DETECTED


The analytical performance characteristics of
T. vaginalis have been determined by Quest Diagnostics.

Page 2
/
3
Patient: Thrivikraman Subramanian
MRN: 5188645
Irene Rummel, PA-C

The
the modifications have
FDA. This assay hasnot
beenbeen clearedpursuant
validated or approved by
to the
CLIA regulations and is used for clinical purposes.
For additional information, please refer to
https:// education.questdiagnostics.com/faq/FAQ154
https://education.questdiagnostics.com/faq/Trichomonastma
(These links are being provided for informational/
educational purposes only.)

RPR (Diagnosis) with Reflex to Titer and Confirmatory Testing (Final Results)

RPR (DX) W/REFL TITER AND CONFIRMATORY TESTING NON-REACTIVE


Normal: NON-REACTIVE Normal
Final

Herpes Simplex Virus 1/2 (IgG) (HerpeSelect®) with Reflex to HSV-2 Inhibition (Final Results)

HSV 1 IGG, TYPE SPECIFIC AB <0.90 index


Normal
Final

HSV 2 IGG, TYPE SPECIFIC AB <0.90 index


Normal
Final

Index Interpretation
----- --------------
<0.90 Negative
0.90-1.09 Equivocal
>1.09 Positive
This assay utilizes recombinant type-specific antigens
to differentiate HSV-1 from HSV-2 infections. A
positive result cannot distinguish between recent and
past infection. If recent HSV infection is suspected
but the results are negative or equivocal, the assay
should be repeated in 4-6 weeks. The performance
characteristics of the assay have not been established
for pediatric populations, immunocompromised patients,
or neonatal screening.
For additional information, please refer to
http://education.QuestDiagnostics.com/faq/FAQ118
(This link is being provided for informational/
educational purposes only.)

Page 3
/
3

You might also like